Werewolf Therapeutics (HOWL) Invested Capital (2022 - 2026)

Werewolf Therapeutics (HOWL) has reported Invested Capital for 5 consecutive years, with $16.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital fell 76.24% year-over-year to $16.3 million in Q2 2026; TTM through Jun 2026 was $16.3 million, a 76.24% decrease from a year earlier, with the FY2025 full-year figure at $53.0 million, down 46.68% from the prior year.
• Invested Capital was $16.3 million for Q2 2026 at Werewolf Therapeutics, down from $41.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $160.1 million in Q1 2023 and troughed at $16.3 million in Q2 2026.
• A 5-year average of $104.2 million and a median of $115.0 million in 2024 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital advanced 23.18% in 2023 and slumped 76.24% in 2026, its largest moves.
• Over 5 years, Invested Capital stood at $122.3 million in 2022, then grew by 23.18% to $150.7 million in 2023, then plunged by 33.98% to $99.5 million in 2024, then tumbled by 46.68% to $53.0 million in 2025, then tumbled by 69.28% to $16.3 million in 2026.
• The last three Invested Capital figures came in at $16.3 million (Q2 2026), $41.0 million (Q1 2026), and $53.0 million (Q4 2025), per Business Quant data.